The Latest Breaking News from NYSE

On CNBC's “Halftime Report Final Trades,” Joe Terranova, senior managing director at Virtus Investment Partners, picked Morgan Stanley (NYSE:MS) as his final trade.

The U.S. Department of Defense (DOD) has awarded Raytheon Co. (NYSE:RTX) a massive $5.04 billion contract for the Coyote Missile System.

Michigan-based automakers Ford Motor Co. (NYSE:F) and General Motors Co. (NYSE:GM) are reportedly working on dedicated programs that could extend the IRA EV credit beyond President Donald Trump's September 30 deadline.

Occidental Petroleum Corporation (NYSE: OXY) shares are trading higher on Monday after reports emerged that the company is in advanced talks to sell its OxyChem petrochemicals division for approximately $10 billion.

Apparel and footwear giant Nike Inc. (NYSE: NKE) could provide an update on its continued turnaround and how tariffs are impacting the business when the company reports first-quarter financial results Tuesday after market close.

Vistra Corp. (NYSE: VST) will add two new natural gas units at its Permian Basin Power Plant in West Texas, expanding the facility’s capacity from 325 megawatts to 1,185 megawatts. The decision comes as electricity use grows across the state, particularly in energy-intensive industries tied to oil and gas.

The Board of AstraZeneca plc (NASDAQ: AZN) is recommending to shareholders a Harmonized Listing Structure for the company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE).

Corpay, Inc. (NYSE: CPAY) and Mastercard Inc. (NYSE: MA) said on Monday they are expanding their partnership to allow companies, small businesses and financial institutions to send near real-time payments to 22 additional markets across Asia, Europe, the Middle East, Africa and Latin America.

The U.S. economy grew at a 3.8% annual rate in the second quarter, its fastest pace since the third quarter of 2023 and above the long-term trend.

On Thursday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Co.’s (NYSE: LLY) Inluriyo (imlunestrant) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET).

On Thursday, the stock market experienced a downturn, with the SP 500 and the Nasdaq both closing lower. The Dow Jones also saw a decline of over 170 points.